Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Ontology highlight
ABSTRACT: This research trial is testing a combination of two experimental drugs, MSC1936369B (Mitogen-activated protein extracellular signal-regulated kinase (MEK) Inhibitor) and SAR245409 (Phosphatidylinositol 3-kinase (Pi3K)/Mammalian Target of Rapamycin (mTOR) inhibitor), in the treatment of locally advanced or metastatic solid tumors. The primary purpose of the study is to determine the maximum tolerated dose of the drug combination.
DISEASE(S): Solid Tumor,Metastatic Solid Tumor,Melanoma,Colorectal Cancer,Non Small Cell Lung Cancer,Breast Cancer,Neoplasms,Locally Advanced Solid Tumor
PROVIDER: 2109499 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA